m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0124)
Name |
Human skin lesions
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: ME60
|
Full List of Target Gene(s) of This m6A-centered Disease Response
E3 ubiquitin-protein ligase NEDD4-like (NEDD4L)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | FTO deletion inhibited arsenic-induced tumorigenesis. Epidermis-specific FTO deletion prevented skin tumorigenesis induced by arsenic and UVB irradiation. E3 ubiquitin-protein ligase NEDD4-like (NEDD4L) was identified as the m6A-modified gene target of FTO. Arsenic stabilizes FTO protein through inhibiting p62-mediated selective autophagy. FTO-mediated dysregulation of mRNA m6A methylation as an epitranscriptomic mechanism to promote arsenic tumorigenicity. Arsenic suppresses p62 expression by downregulating the NF-Kappa-B pathway to upregulate FTO. | |||
Responsed Disease | Human skin lesions [ICD-11: ME60] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Cellular Processes, Transport and catabolism | |||
Cell autophagy | ||||
In-vitro Model | HaCaT | Normal | Homo sapiens | CVCL_0038 |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
MEF (Mouse embryonic fibroblasts) | ||||
In-vivo Model | As cells (5 million) in Matrigel or As-T (1 million) cells in PBS with or without gene manipulations were injected subcutaneously into the right flanks of female mice (6-8 weeks of age). For treatment with CS1 or CS2, As-T cells (1 million) in PBS were injected subcutaneously into the right flanks of 6-week-old female nude mice. | |||
Sequestosome-1 (SQSTM1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | FTO deletion inhibited arsenic-induced tumorigenesis. Epidermis-specific FTO deletion prevented skin tumorigenesis induced by arsenic and UVB irradiation. NEDD4L was identified as the m6A-modified gene target of FTO. Arsenic stabilizes FTO protein through inhibiting Sequestosome-1 (SQSTM1)-mediated selective autophagy. FTO-mediated dysregulation of mRNA m6A methylation as an epitranscriptomic mechanism to promote arsenic tumorigenicity. Arsenic suppresses p62 expression by downregulating the NF-Kappa-B pathway to upregulate FTO. | |||
Responsed Disease | Human skin lesions [ICD-11: ME60] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Autophagy | hsa04140 | ||
Cell Process | Cellular Processes, Transport and catabolism | |||
Cell autophagy | ||||
In-vitro Model | HaCaT | Normal | Homo sapiens | CVCL_0038 |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | |
MEF (Mouse embryonic fibroblasts) | ||||
In-vivo Model | As cells (5 million) in Matrigel or As-T (1 million) cells in PBS with or without gene manipulations were injected subcutaneously into the right flanks of female mice (6-8 weeks of age). For treatment with CS1 or CS2, As-T cells (1 million) in PBS were injected subcutaneously into the right flanks of 6-week-old female nude mice. | |||